Strides Pharma Gets USFDA Nod for Generic Pregabalin
Strides Pharma Science subsidiary receives USFDA approval for generic Pregabalin capsules, a medication for nerve pain. The product is bio-equivalent to Lyrica capsules and has a market size of USD 248 million in the US.
Photograph: Yves Herman/Reuters
New Delhi, Jan 25 (PTI) Strides Pharma Science on Thursday said its subsidiary has received approval from the US health regulator for a generic medication for nerve pain.
Singapore-based Strides Pharma Global Pte has received approval for Pregabalin capsules from the US Food & Drug Administration (USFDA), the drug maker said in a regulatory filing.
The company's product is bio-equivalent and therapeutically equivalent to the reference listed drug -- Lyrica capsules -- used in the treatment of fibromyalgia.
As per IQVIA data, Pregabalin capsules have a market size of USD 248 million in the US market.
Shares of Strides Pharma Science on Thursday ended 2.27 per cent up at Rs 685.75 apiece on the BSE.
Singapore-based Strides Pharma Global Pte has received approval for Pregabalin capsules from the US Food & Drug Administration (USFDA), the drug maker said in a regulatory filing.
The company's product is bio-equivalent and therapeutically equivalent to the reference listed drug -- Lyrica capsules -- used in the treatment of fibromyalgia.
As per IQVIA data, Pregabalin capsules have a market size of USD 248 million in the US market.
Shares of Strides Pharma Science on Thursday ended 2.27 per cent up at Rs 685.75 apiece on the BSE.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone-Idea-L
- 10.29 ( -4.72)
- 71162549
- Spicejet-Ltd
- 32.50 (+ 4.47)
- 59158929
- Alstone-Textiles
- 0.30 ( 0.00)
- 37245425
- Sunshine-Capital
- 0.25 ( 0.00)
- 25623281
- G-V-Films
- 0.63 ( -4.55)
- 21918363
MORE NEWS
© 2025 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback